189 related articles for article (PubMed ID: 21052789)
21. The prostaglandin E2 receptor, EP2, stimulates keratinocyte proliferation in mouse skin by G protein-dependent and {beta}-arrestin1-dependent signaling pathways.
Chun KS; Lao HC; Langenbach R
J Biol Chem; 2010 Dec; 285(51):39672-81. PubMed ID: 20959465
[TBL] [Abstract][Full Text] [Related]
22. Target modulation by a kinase inhibitor engineered to induce a tandem blockade of the epidermal growth factor receptor (EGFR) and c-Src: the concept of type III combi-targeting.
Rao S; Larroque-Lombard AL; Peyrard L; Thauvin C; Rachid Z; Williams C; Jean-Claude BJ
PLoS One; 2015; 10(2):e0117215. PubMed ID: 25658745
[TBL] [Abstract][Full Text] [Related]
23. Src kinases catalytic activity regulates proliferation, migration and invasiveness of MDA-MB-231 breast cancer cells.
Sánchez-Bailón MP; Calcabrini A; Gómez-Domínguez D; Morte B; Martín-Forero E; Gómez-López G; Molinari A; Wagner KU; Martín-Pérez J
Cell Signal; 2012 Jun; 24(6):1276-86. PubMed ID: 22570868
[TBL] [Abstract][Full Text] [Related]
24. Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.
Restelli V; Chilà R; Lupi M; Rinaldi A; Kwee I; Bertoni F; Damia G; Carrassa L
Oncotarget; 2015 Nov; 6(35):37229-40. PubMed ID: 26439697
[TBL] [Abstract][Full Text] [Related]
25. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X
Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of Src kinase blocks high glucose-induced EGFR transactivation and collagen synthesis in mesangial cells and prevents diabetic nephropathy in mice.
Taniguchi K; Xia L; Goldberg HJ; Lee KW; Shah A; Stavar L; Masson EA; Momen A; Shikatani EA; John R; Husain M; Fantus IG
Diabetes; 2013 Nov; 62(11):3874-86. PubMed ID: 23942551
[TBL] [Abstract][Full Text] [Related]
28. Src family kinase inhibitors blunt PACAP-induced PAC1 receptor endocytosis, phosphorylation of ERK, and the increase in cardiac neuron excitability.
Tompkins JD; Clason TA; Buttolph TR; Girard BM; Linden AK; Hardwick JC; Merriam LA; May V; Parsons RL
Am J Physiol Cell Physiol; 2018 Feb; 314(2):C233-C241. PubMed ID: 29141923
[TBL] [Abstract][Full Text] [Related]
29. An anti-Ras cancer potential of PP1, an inhibitor specific for Src family kinases: in vitro and in vivo studies.
He H; Hirokawa Y; Levitzki A; Maruta H
Cancer J; 2000; 6(4):243-8. PubMed ID: 11038144
[TBL] [Abstract][Full Text] [Related]
30. Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis.
Nagaraj NS; Smith JJ; Revetta F; Washington MK; Merchant NB
Mol Cancer Ther; 2010 Aug; 9(8):2322-32. PubMed ID: 20682659
[TBL] [Abstract][Full Text] [Related]
31. Src tyrosine kinase inhibitor PP2 suppresses ERK1/2 activation and epidermal growth factor receptor transactivation by X-irradiation.
Li Z; Hosoi Y; Cai K; Tanno Y; Matsumoto Y; Enomoto A; Morita A; Nakagawa K; Miyagawa K
Biochem Biophys Res Commun; 2006 Mar; 341(2):363-8. PubMed ID: 16414009
[TBL] [Abstract][Full Text] [Related]
32. c-Src regulates cell cycle proteins expression through protein kinase B/glycogen synthase kinase 3 beta and extracellular signal-regulated kinases 1/2 pathways in MCF-7 cells.
Liu X; Du L; Feng R
Acta Biochim Biophys Sin (Shanghai); 2013 Jul; 45(7):586-92. PubMed ID: 23615537
[TBL] [Abstract][Full Text] [Related]
33. Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.
Fraser C; Dawson JC; Dowling R; Houston DR; Weiss JT; Munro AF; Muir M; Harrington L; Webster SP; Frame MC; Brunton VG; Patton EE; Carragher NO; Unciti-Broceta A
J Med Chem; 2016 May; 59(10):4697-710. PubMed ID: 27115835
[TBL] [Abstract][Full Text] [Related]
34. Protein-tyrosine-phosphatase-mediated epidermal growth factor (EGF) receptor transinactivation and EGF receptor-independent stimulation of mitogen-activated protein kinase by bradykinin in A431 cells.
Graness A; Hanke S; Boehmer FD; Presek P; Liebmann C
Biochem J; 2000 Apr; 347(Pt 2):441-7. PubMed ID: 10749673
[TBL] [Abstract][Full Text] [Related]
35. Src kinase family inhibitor PP2 induces aggregation and detachment of neuroblastoma cells and inhibits cell growth in a PI3 kinase/Akt pathway-independent manner.
Hishiki T; Saito T; Sato Y; Mitsunaga T; Terui E; Matsuura G; Saito E; Shibata R; Mise N; Yokoyama Y; Yoshida H
Pediatr Surg Int; 2011 Feb; 27(2):225-30. PubMed ID: 21046121
[TBL] [Abstract][Full Text] [Related]
36. Src family kinases mediate epidermal growth factor receptor signaling from lipid rafts in breast cancer cells.
Irwin ME; Bohin N; Boerner JL
Cancer Biol Ther; 2011 Oct; 12(8):718-26. PubMed ID: 21775822
[TBL] [Abstract][Full Text] [Related]
37. Antiproliferative and pro-apoptotic effects afforded by novel Src-kinase inhibitors in human neuroblastoma cells.
Navarra M; Celano M; Maiuolo J; Schenone S; Botta M; Angelucci A; Bramanti P; Russo D
BMC Cancer; 2010 Nov; 10():602. PubMed ID: 21050441
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells.
Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Wang NJ; Zhao RJ; Zhou SF
Drug Des Devel Ther; 2015; 9():487-508. PubMed ID: 25609923
[TBL] [Abstract][Full Text] [Related]
39. Involvement of Cx43 phosphorylation in 5'-N-ethylcarboxamide-induced migration and proliferation of mouse embryonic stem cells.
Kim MO; Lee YJ; Han HJ
J Cell Physiol; 2010 Jul; 224(1):187-94. PubMed ID: 20232318
[TBL] [Abstract][Full Text] [Related]
40. A preclinical evaluation of SKLB261, a multikinase inhibitor of EGFR/Src/VEGFR2, as a therapeutic agent against pancreatic cancer.
Pan Y; Zheng M; Zhong L; Yang J; Zhou S; Qin Y; Xiang R; Chen Y; Yang SY
Mol Cancer Ther; 2015 Feb; 14(2):407-18. PubMed ID: 25519702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
